PT-141 vs Sermorelin
Vyleesi
PT-141 and Sermorelin are both peptide compounds evaluated on Vial: PT-141 is FDA approved with FDA-approval-level clinical evidence, and Sermorelin is legally compoundable with clinical-trial evidence, offered by 9 and 27 verified providers respectively.
Vial summary · compiled from public records
At a glance
PT-141
Sold as Vyleesi
- Category
- Peptide
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
Sermorelin
- Category
- Peptide
- FDA / legal status
- Legally Compoundable
- Route
- Subcutaneous
Side by side
| Field | PT-141 | Sermorelin |
|---|---|---|
| Category | Peptide | Peptide |
| Brand names | Vyleesi | — |
| FDA / legal status | FDA Approved | Legally Compoundable |
| Evidence tier | FDA Approved | Clinical Trials |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | FDA-approved product, dispensed by prescription | Legally Compoundable |
| Providers on Vial | 9 listed | 27 listed |
| Typical price band | $$ | $$ to $$$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About PT-141
A synthetic cyclic heptapeptide melanocortin receptor agonist, bremelanotide (PT-141) acts primarily on MC4 receptors in the central nervous system to modulate sexual arousal pathways. The compound increases sexual desire through direct neurological mechanisms rather than peripheral vascular effects. Its primary clinical application is the treatment of hypoactive sexual desire disorder in premenopausal women.
About Sermorelin
A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.